The quest for a vaccine against HIV has been going on for about 40 years — almost as long as the virus that causes AIDS has been known to scientists and the public. There has been some progress ...

Steven Hatfill, a senior biosecurity adviser at the Department of Health and Human Services (HHS), was dismissed after ...

A commonly used strategy in the development of messenger RNA (mRNA) medicine is based on the destruction of disease-causing mRNA. Achieving the opposite and stabilizing health-promoting mRNA is still ...

Historically, RSV has been associated with infants, but they are not the only group that can be affected by serious RSV ...

A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at ...

Lung cancer and melanoma patients immunized with this formula doubled their chances of surviving three years, according to a ...

Further validating the results, University of Florida researchers found that tying cancer immunotherapies with COVID-targeted ...

Exsilio Therapeutics has launched with $82 million in series A funding. Exsilio uses lipid nanoparticles and messenger RNA (mRNA) to integrate whole corrective genes into “safe harbors” in the ...

Moderna is expected to announce its third-quarter results next month, and analysts expect a significant loss per share.

mRNA transports the most valuable cellular information - the chemical blueprint for the production of proteins - from the nucleus into the cytoplasm. However, as soon as mRNA has delivered its message ...